Megaport Limited

MP1

Megaport Ltd. engages in the provision of software-defined networking based elastic interconnection services. The company is headquartered in Fortitude Valley, Queensland. The company went IPO on 2015-12-17. The Company’s global software defined network (SDN) helps businesses connect their network to services through an easy-to-use portal or its open application programming interface (API). The company offers agile networking capabilities. The Company’s segments include North America, Asia Pacific, and Europe. Its products include Port, Virtual Cross Connects (VXC), Megaport Cloud Router (MCR), Megaport Virtual Edge (MVE), Megaport Marketplace and MegaIX. VXCs are Layer 2 Ethernet circuits providing private, flexible, and on-demand connections between any of the locations on the Megaport network with 1 Mbps to 10 Gbps of capacity. MCR is a managed virtual router service. MVE is an on-demand, vendor-neutral network function virtualization (NFV) service. Megaport Marketplace is an online hub where global service providers and enterprise customers interconnect.

iShares S&P 500 ETF

IVV

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

Chalice Mining Limited

CHN

Chalice Mining Ltd. is a mineral exploration company, which engages in the development of mineral projects. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-03-24. The firm is engaged in the exploration and evaluation of the Gonneville Nickel-Copper-PGE Project and the exploration of projects located in the West Yilgarn region of Western Australia. The Gonneville Platinum Group Element-Nickel-Copper-Cobalt (PGE-Ni-Cu-Co) is a development project located on Chalice-owned farmland, in Western Australia. Gonneville PGE-Ni-Cu-Co Project is located on Chalice-owned farmland over 70 kilometers north-east of Perth, Western Australia. Its projects include Julimar Nickel-Copper-PGE Exploration Project, Kings Nickel-Copper-PGE Exploration Project, Northam Resources Joint Venture Nickel-Copper-PGE Exploration Project, Barrabarra Nickel-Copper-PGE Exploration Project, South West Nickel-Copper-PGE Exploration Project, Narryer Nickel-Copper-PGE Exploration Project, Auralia Nickel-Copper-PGE Exploration Project, Warrego North Copper-Gold Exploration Project and Nulla South Gold Exploration Project.

Australian Vanadium Limited

AVL

Australian Vanadium Ltd. engages in the development and exploration of mineral properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2007-02-21. The Exploration segment includes Australian Vanadium Project and other exploration projects. The Energy storage segment include VSUN Energy Pty Limited's vanadium redox flow battery marketing and sales activities. The Electrolyte Plant segment is its vanadium electrolyte manufacturing facility in Western Australia. The Australian Vanadium Project consists of V-Ti-Fe deposit located in the Murchison Province 43 kilometers (kms) south of the mining town of Meekatharra in Western Australia and 740 km north-east of Perth. The Project consists of 15 tenements covering 200 square km. The Coates Project is located in the Shire of Northam, approximately 60 km east of Perth. The Nowthanna Hill deposit is located 50 km south of Meekatharra.

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the provision of business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The Company’s lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).